

Market Update

Consumer Health Post-3Q 2024 Update

November 2024

Table of Contents

Section One — Consumer Health Update

	i. Consumer Market Update & Outlook	5					
	ii. Relevant Transactions	6					
	iii. Bourne Public Comps	7					
	iii. Bourne Pharma Services Indices	10					
Section Two — Bourne Partners							
	i. Thought Leadership	12					
	ii. Bourne Partners Overview	13					
	iii. Investment Bank Overview	14					



Don Hooker Director of Research dhooker@bourne-partners.com +1 980-414-0945



Jeremy Johnson Senior Managing Director, Head of IB jjohnson@bourne-partners.com +1 704-201-2323



Robert Stanley Director rstanley@bourne-partners.com +1 336-655-6928



Todd Bokus Director tbokus@bourne-partners.com +1 704-807-7501



Carson Riley Vice President criley@bourne-partners.com +1 615-483-9689



Nick Triantafyllides Associate nickt@bourne-partners.com +1 704-779-6992

Bourne's Consumer Health Expertise

Consumer Health Sector Expertise



Transaction Experience

Sell-Side & Buy-Side M&A

Product & Portfolio Transactions

Capital Raising

Global In / Out-Licensing



Subsector Expertise

Over-the-Counter Medicine

Vitamins, Minerals & Supplements



Personal Care & Wellness

Functional Ingredients



Manufacturing (CDMO/CMO)

Packaging / Distribution / Logistics

Commercialization Services

Consumer Health Strategic Advisors



Scott Emerson, Strategic Advisor Founder & CEO of The Emerson group 30+ years of industry experience Relationships with all major retailers and brands



Bruce Montgomery, Strategic Advisor Former Head of Commercial at Fleet Laboratories 30+ years of consumer & retail experience Strong history of developing and growing brands



Pharma Services Healthcare Services

Consumer Healthcare

Representative Consumer Health Transactions




















Consumer Health Market Update

Sector Thesis

Growth of the Consumer Health market (valued at \$350B) is being driven an aging population, an elevated focus on preventive healthcare, and an expanding middle class. However, growth trends have been obfuscated by volatility caused by the COVID-19 pandemic. In our view, many larger consumer companies have not focused on innovation, creating an opportunity for middle-market brand aggregators. These middle-market brand aggregators, in turn, have successfully embraced social media, influencer marketing, and AI-driven sales strategies.

Over-the-Counter (OTC) Medicine

- The OTC market has experienced significant volatility due to the impact of the COVID-19 pandemic on demand for cough, cold, and flu products. Demand trends are starting to normalize in 2024.
- Rx-to-OTC switches have been a focus in the OTC market. The FDA has been actively encouraging Rxto-OTC switches, and brands scheduled to come off-patent could be profitable targets.
- Women's health products are growing faster than the overall OTC market, and the recent Rx-to-OTC switch of Perrigo's contraceptive, Opill, has created a new category in this space.

Vitamins, Minerals & Supplements (VMS)

- VMS demand has normalized to a historical growth rate in the mid-single digits. Post-COVID, general awareness of preventive health has continued to be an underlying driver of demand.
- Nutritional support programs and active lifestyle supplements, including proteins and multivitamins, are emerging as a new driver among a growing number of patients using GLP-1 medications.

Personal Care & Wellness (PCW)

- The PCW market exceeds \$5B+ annually, with an expected annual growth of ~6%. The market consists of a very broad spectrum of products ranging from health, appearance, fitness, nutrition, mindfulness, and sleep -- beyond the traditional categories of OTC and VMS.
- We have been monitoring the ongoing trend towards "clean" personal care -- consisting of shampoos, deodorants, beauty supplies, and other products being made with natural ingredients. This a largely unregulated term created in response to the otherwise limited regulation in many of these industries.

Select Market Players




























































Select Consumer Health Transactions

Date	Target	Acquirer		Commentary	Tags	Deal Values
Aug-2024	REVANCE THERAPE	UTICS	CROWN	Aesthetic and therapeutic offerings, including DAXXIFY for injection and the RHA Collection of dermal fillers	Personal Care	\$1,212M
May-2024	PURA	A VC	vector consumer	The acquisition aligns with Vector Consumer's goal to become a leading authority in the collagen industry	VMS	Undisclosed
May-2024	LUCAS ME	YER CLA	RIANT	Enhancing Clariant's presence in the cosmetic market, supporting its growth strategy and innovation	Personal Care	\$810M
Jan-2024	ChapSi	tick	Suave PROFESSIONALS	Expanding Suave's market presence in the lip care segment by leveraging ChapSticks's brand recognition	Personal Care	\$510M
Jan-2024	Viact	tiv .	DOGIOSS BEST Science Based Nutrition	Expanding the Doctor's Best's retail distribution and providing more convenient, tasty supplement options	VMS	\$17M
Oct-2023	F C C	U S	KOBAYASHI	The acquisition represents Kobayashi's strategy to expand its international presence	отс	\$75M
Jun-2023	A Ri hea	O alth [™]	ARCADIA ONSUMER HEALTHCARE	The acquisition will enhance Arcadia's portfolio of high- quality products and solutions	отс	\$397M
Apr-2023	A+D® Solarc Cortate© Complex 1	® We	ellSpring V	WellSpring's strategy to expand product offerings by adding established OTC brands to its portfolio	отс	Undisclosed
Jan-2023	soyler	nt 💦	STARCO brands	Starco Brands continues to invent and acquire behavior-changing technologies and brands	VMS	\$67M
Aug-2022	PAR CL	II M	ondelez,	Mondelez aims to gain significant top-line synergies, including deeper distribution and channel expansion	Personal Care	\$2.6B




Bourne Comps - Over-the-Counter (OTC) Medicine



			Cash & Cash	Enterprise			EV / LTM	EV / LTM
Company Name	Market Cap	Total Debt	Eqv	Value	LTM Revenue	LTM EBITDA	Revenue	EBITDA
отс								
Rohto Pharmaceutical Co.,Ltd.	\$4,044	\$311	\$450	\$3,905	\$1,969	\$320	2.0x	12.2x
Kenvue Inc.	45,266	8,827	1,057	53,036	15,459	3,454	3.4x	15.4x
Reckitt Benckiser Group plc	41,524	11,506	1,246	51,783	18,108	4,474	2.9x	11.6x
Haleon plc	41,890	12,131	712	53,309	15,065	3,599	3.5x	14.8x
Genomma Lab Internacional, S.A.B. de C.V.	1,239	336	93	1,482	892	201	1.7x	7.4x
Perrigo Company plc	3,674	4,989	1,462	7,200	4,392	572	1.6x	12.6x
Boiron SA	568	16	57	527	516	69	1.0x	7.6x
Alliance Pharma plc	322	134	24	431	231	65	1.9x	6.6x
Prestige Consumer Healthcare Inc.	4,090	1,061	52	5,100	1,111	357	4.6x	14.3x
			Mean (Equal W	eighted)	\$6,416	\$1,457	2.5x	11.4x
			Median (Equal	Weighted)	\$1,969	\$357	2.0x	12.2x



Bourne Comps - Vitamins, Minerals & Supplements (VMS)




3,015 9,366 3,740	Total Debt 102 839	Eqv 471 73	Value 2,645	LTM Revenue	LTM EBITDA	Revenue 2.5x	EBITDA 21.8v
9,366	839		•	1,049	122	2.5x	21 8v
9,366	839		•	1,049	122	2.5x	21.8x
•		73				2.5%	21.00
3,740		, ,	10,133	1,913	399	5.3x	25.4x
	437	133	4,045	1,331	250	3.0x	16.2x
777	2,471	403	2,845	5,001	546	0.6x	5.2x
173	13	15	172	196	10	0.9x	17.9x
800	1,320	335	1,785	1,877	253	1.0x	7.1x
1,048	335	31	1,351	525	75	2.6x	18.1x
75	1,485	57	1,504	807	130	1.9x	11.6x
296	15	79	232	445	40	0.5x	5.8x
		• •	•	\$1,460 \$1,049	\$203 \$120	2.0x	14.3x 16.2x
	173 800 1,048 75	173 13 800 1,320 1,048 335 75 1,485 296 15	173 13 15 800 1,320 335 1,048 335 31 75 1,485 57 296 15 79 Mean (Equal W	173 13 15 172 800 1,320 335 1,785 1,048 335 31 1,351 75 1,485 57 1,504	173 13 15 172 196 800 1,320 335 1,785 1,877 1,048 335 31 1,351 525 75 1,485 57 1,504 807 296 15 79 232 445 Mean (Equal Weighted) \$1,460	173 13 15 172 196 10 800 1,320 335 1,785 1,877 253 1,048 335 31 1,351 525 75 75 1,485 57 1,504 807 130 296 15 79 232 445 40 Mean (Equal Weighted) \$1,460 \$203	173 13 15 172 196 10 0.9x 800 1,320 335 1,785 1,877 253 1.0x 1,048 335 31 1,351 525 75 2.6x 75 1,485 57 1,504 807 130 1.9x 296 15 79 232 445 40 0.5x Mean (Equal Weighted) \$1,460 \$203 2.0x

Note: Market values as of the close of business November 15, 2024. Source: S&P Global Market Intelligence




Bourne Comps - Personal Care & Wellness (PCW)





Bourne Consumer Health Indices







Thought Leadership

Bourne Perspective

After 20+ years of exclusive industry and capital markets coverage, we know the space and we are committed to providing insights to clients. We provide cutting-edge thought leadership on all things Pharma, Pharma Services, Healthcare Services, and Consumer Health.


Through leveraging resources and insights of both Bourne Partners Strategic Capital and Investment Banking divisions, we provide differentiated perspectives to our clients from our unique vantage point. Our goal is to deliver heavy-hitting, timely reports in an easy-to-read format tailored specifically for executives within our industry coverage.

Substance Use

ectives and Research on the

ce Use Disorders Space

Disorder Update




Clinical Trial

Site Networks

Market Research Report

September 12, 2024







Bourne Partners Overview

Our Service Offering

For over twenty years, Bourne Partners has focused exclusively on providing investment banking advisory services and making direct investments in the Pharmaceutical, Healthcare Services, Pharmacy Services, and Consumer Health spaces.

Since 2015, we have successfully executed on over \$15B in transactions, having worked with many leading companies and private equity investors in these core focus areas.

Investment Banking

Mergers and Acquisitions

Sell-side and buy-side assignments Transaction Experience: \$10M - \$3.5B

Capital Sourcing

Debt / Equity / Hybrid \$10 - \$500 million raises

Business Development Support

Development stage and approved products Local and international

Strategic Capital

Investment Focus

Direct investments in private companies Selective approach in vital focus areas

Other Criteria

Cash flow positive opportunities Complex situations with creative structures Actionable growth stage or middle market business

Flexible investment targets with established private equity relationships

Geographic Coverage



Sector Expertise





Investment Banking Overview

Bourne Partners Investment Banking provides investment banking services within the healthcare and life sciences sectors for external clients as well as our portfolio companies.

Value Beyond the Deal

Total Perspective

Experience advising, investing in, building, operating, buying, and selling companies Unmatched 360° perspective for every project

Uncompromised Service

Direct involvement of senior management through the process

High level of attention regardless of transaction value

Global Reach

Experience working with companies around the globe Extensive network of potential international buyers

Focus Areas

Buy and Sell Side M&A

Equity & Debt Capital

Licensing / **Partnering**

Strategic Consulting

Select Recent Tombstones













Partners, Sponsors, and Lenders













Recent Clients & Counterparties

























